Review Article
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
Table 2
Cost of guideline recommended therapies for HCV genotype 1a [
33].
| | | Elbasvir-grazoprevir (Zepatier) | Simeprevir (Olysio) + sofosbuvir (Sovaldi) | Ledipasvir-sofosbuvir (Harvoni) | Ombitasvir-paritaprevir-ritonavir-dasabuvir (Viekira) + ribavirin | Daclatasvir (Daklinza) + sofosbuvir (Sovaldi) |
| | 8 weeks | NA | NA | 63,000 | NA | NA | | 12 weeks | 54,600 | 150,000 | 94,500 | 84,019 | 147,000 | | 16 weeks | 72,800 | NA | NA | NA | NA | | 24 weeks | NA | NA | 189,000 | 168,038 | NA |
|
|
NA: not applicable.
|
